- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02699996
Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors
Promoting Follow-Up Care Self-Management for Adolescent and Young Adult (AYA) Childhood Cancer Survivors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of the self-management + peer mentoring program in a pilot trial.
II. Assess preliminary outcomes of the peer mentoring program.
OUTLINE:
All Participants will be asked to complete online self-management educational modules and 6 weekly peer mentor calls to facilitate engagement with the online modules and offer specialized support. We will also recruit and train peer Mentors.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
PEER MENTOR ELIGIBILITY:
- Age 21-29
- At least 1.5 years from treatment
- Self-reported primary responsibility for care and "complete readiness" using the Readiness for Transition Questionnaire
PATIENT ELIGIBILITY:
- Age 18-25
- At least 1.5 years from treatment
- Currently does not independently self-manage follow-up care according to self-report to assume total responsibility for care (i.e., reports low readiness [score of 1 or 2 out of 4] OR scores <3 on any of the 10-item responsibility scale from the Readiness for Transition Questionnaire)
Exclusion Criteria:
PATIENT EXCLUSION CRITERIA: Physician- or self-reported cognitive delay or impairment that would prevent self-management of healthcare
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: self-management + peer mentoring
Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
|
Complete interview
Complete the self management + peer mentoring intervention with videoconferencing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility as Measured by Study Enrollment Rates, Retention Rates, Adherence to the Intervention, and Reasons for Study Drop Out.
Time Frame: 6 weeks
|
Descriptive analyses will be used to evaluate expected enrollment (> 50%), retention (> 80%), and completion of intervention sessions (> 75%).
|
6 weeks
|
Satisfaction With Intervention, Measured by 1) General Satisfaction, 2) Intervention Utility Questionnaire, 3) Impact Questionnaire (i.e., Effectiveness), and 4) Adherence Questionnaire ( i.e., Barriers to Engagement).
Time Frame: 6 weeks (post-intervention)
|
|
6 weeks (post-intervention)
|
Mentor Training Satisfaction
Time Frame: Time of enrollment, after completing mentor training.
|
Mentor 6-item Training Satisfaction measured on a scale from 1 "strongly disagree" to 4 "strongly agree" (higher score=high satisfaction).
Administered to Group Intervention Mentors only.
Total average score is reported.
|
Time of enrollment, after completing mentor training.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transition Readiness, as Measured by the Readiness for Transition Questionnaire - Survivor Version
Time Frame: Baseline to up to 6 weeks
|
Respondents rate how responsible they are for various healthcare tasks on a 4-point scale, where 1= "not responsible at all", and 4= "almost always responsible."
The Adolescent Responsibility Scale is calculated by averaging responses across all 10 items (RTQ-Survivor).
A single item assessing "overall readiness to assume complete responsibility for health care" on the same 4-point scale is analyzed separately.
|
Baseline to up to 6 weeks
|
Transition Readiness, as Measured by the Transition Readiness Inventory (Phase 2).
Time Frame: Baseline to up to 6 weeks
|
The Transition Readiness Inventory (TRI) yields six sub-scale scores: Knowledge, Skills/Self-Efficacy, Beliefs/Expectations, Goals/Motivation, Relationship/Communication, and Psychosocial/Emotional.
Total average score is reported across all sub-scales (TRI-total), as well as each sub-scale total score.
Scores are averaged across items on a 5-point scale from 1 "not at all" to 5 "extremely" or "always," with higher scores indicating better functioning.
|
Baseline to up to 6 weeks
|
Symptoms of Depression, as Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short-Form (v1.0 8b).
Time Frame: Baseline to up to 6 weeks
|
Respondents report symptoms on a 5-point rating scale from 1 "never" to 5 "always" in the past 7 days, with higher scores indicating higher levels of negative affect.
A total raw summary score is calculated and then translated into a standardized T-score with a mean of 50 and standard deviation of 10.
|
Baseline to up to 6 weeks
|
Symptoms of Anxiety, as Measured by the PROMIS Anxiety Short-Form (v1.0 8a)
Time Frame: Baseline to up to 6 weeks
|
Respondents report symptoms on a 5-point rating scale from 1 "never" to 5 "always" in the past 7 days, with higher scores indicating higher levels of negative affect.
A total raw summary score is calculated and then translated into a standardized T-score with a mean of 50 and standard deviation of 10.
|
Baseline to up to 6 weeks
|
Cancer Related Worry Scale
Time Frame: Baseline to up to 6 weeks
|
This 4-item scale is measuring cancer-related worries (i.e., recurrence of cancer, future diagnostic tests, cancer coming back, other type of cancer).
A total score is calculated by averaging across items on a 5-point scale (from 1="Strongly disagree" to 5="Strongly agree"), with higher scores indicating greater worry.
Total average score is reported.
|
Baseline to up to 6 weeks
|
Short Grit Scale
Time Frame: Baseline to up to 6 weeks
|
Perseverance is measured via the The Short Grit Scale, an 8-item measure of perseverance for long-term goals.
A total scale score is calculated by averaging across all items, on a 5-point scale (from 1 "not at all like me" to 5 "very much like me"), with higher scores indicating greater perseverance.
|
Baseline to up to 6 weeks
|
Impact of Cancer, as Measured by Three Subscales of the Impact of Cancer - Childhood Cancer Survivors Scale
Time Frame: Baseline to up to 6 weeks
|
The three subscales measure perceptions of cancer impact on Body Health (8 items), Personal Growth (5 items), and Memory Problems (4 items).
Sub-scales are scored by averaging across items using a 5-point scale (where 1="not at all", and 5="very much"), with higher scores indicating greater impact.
|
Baseline to up to 6 weeks
|
Barriers to Follow-up Care & Adherence
Time Frame: Up to 6 weeks
|
Barriers to follow-up care & adherence evaluated by insurance status, current provider, and other barriers to care using 6 items from the Follow-Up Care Use and Health Outcomes of Cancer Survivors (FOCUS).
Participants report on appointments, cancer screening, and other adherence markers on a 5-point scale (from 1="Strongly disagree" to 5="Strongly agree"), where higher score indicates grater barrier.
Total average score is reported.
|
Up to 6 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Katie Devine, Rutgers Cancer Institute of New Jersey
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Pro20150001955
- P30CA072720 (U.S. NIH Grant/Contract)
- 131507 (Other Identifier: Rutgers Cancer Institute of New Jersey)
- NCI-2015-02098 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer Survivor
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterCompleted
-
Ohio State University Comprehensive Cancer CenterCompletedCancer SurvivorUnited States
-
University Health Network, TorontoPrincess Margaret Hospital, Canada; Canadian Breast Cancer FoundationCompletedBreast Cancer Survivor | Pediatric Cancer SurvivorCanada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Oncology Nursing Society; Villanova UniversityCompletedChildhood Cancer SurvivorUnited States
-
Turku University HospitalLounais-Suomen SyöpäyhdistysNot yet recruiting
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnCancer SurvivorUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityCompleted
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completed
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)CompletedCancer SurvivorUnited States
-
Masonic Cancer Center, University of MinnesotaCompleted
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation